Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat. Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival, and is under development for the treatment of blood-related cancers.
www.prnewswire.com/news-releases/cell-therapeutics-announces-removal-of-the-partial-clinical-hold-on-tosedostat-238405421.html
www.prnewswire.com/news-releases/cell-therapeutics-announces-removal-of-the-partial-clinical-hold-on-tosedostat-238405421.html
No comments:
Post a Comment